Massachusetts-based VC shop Atlas Venture has drawn together another $450 million fund to be channeled toward innovative biotechs. The firm’s fourteenth fund is the same amount to the cent as Atlas’ thirteenth fund back in March 2022. The firm has been busy since then, launching 16 new biotechs and recruiting “approximately 100 executive leaders across its portfolio” in the past two years, it explained in a Dec. 5 release. Atlas’ companies have also kept up the pace in those years, with the firm pointing to Eli Lilly’s acquisition of Versanis Bio last year, GSK paying $1 billion for Aiolos Bio in January and Novartis paying the same amount for Mariana Oncology in May. Meanwhile, Disc Medicine, Korro Bio, Q32 Bio and Third Harmonic Bio have gone public, Atlas noted. “Core to Atlas is a disciplined approach to our firm, funds, and portfolio,” the company said in the release. “We believe deeply in the power of a focused venture creation strategy, building biotech companies across the spectrum of disease areas, modalities, and business models.”

Full report : Atlas unveils a new $450M fund targeted at biotechs 2 years after its last.